nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—ADRA2A—epilepsy syndrome	0.456	1	CbGaD
Droxidopa—SLC6A2—locus ceruleus—epilepsy syndrome	0.00837	0.0914	CbGeAlD
Droxidopa—DDC—telencephalic ventricle—epilepsy syndrome	0.00833	0.091	CbGeAlD
Droxidopa—Hyperpyrexia—Diazepam—epilepsy syndrome	0.00656	0.0357	CcSEcCtD
Droxidopa—Hyperpyrexia—Felbamate—epilepsy syndrome	0.00635	0.0346	CcSEcCtD
Droxidopa—DDC—ganglion—epilepsy syndrome	0.00518	0.0567	CbGeAlD
Droxidopa—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00445	0.0486	CbGeAlD
Droxidopa—DDC—hindbrain—epilepsy syndrome	0.00393	0.043	CbGeAlD
Droxidopa—Myocardial ischaemia—Propofol—epilepsy syndrome	0.0034	0.0185	CcSEcCtD
Droxidopa—SLC6A2—ganglion—epilepsy syndrome	0.00247	0.027	CbGeAlD
Droxidopa—DDC—brainstem—epilepsy syndrome	0.00225	0.0246	CbGeAlD
Droxidopa—PAH—head—epilepsy syndrome	0.00218	0.0239	CbGeAlD
Droxidopa—DDC—forebrain—epilepsy syndrome	0.00217	0.0238	CbGeAlD
Droxidopa—Blood pressure increased—Carbamazepine—epilepsy syndrome	0.00212	0.0115	CcSEcCtD
Droxidopa—PAH—nervous system—epilepsy syndrome	0.00207	0.0226	CbGeAlD
Droxidopa—Cardiac failure congestive—Fosphenytoin—epilepsy syndrome	0.00204	0.0111	CcSEcCtD
Droxidopa—DDC—telencephalon—epilepsy syndrome	0.002	0.0219	CbGeAlD
Droxidopa—PAH—central nervous system—epilepsy syndrome	0.00199	0.0218	CbGeAlD
Droxidopa—Syncope—Amobarbital—epilepsy syndrome	0.00193	0.0105	CcSEcCtD
Droxidopa—Loss of consciousness—Amobarbital—epilepsy syndrome	0.00189	0.0103	CcSEcCtD
Droxidopa—Myocardial ischaemia—Pregabalin—epilepsy syndrome	0.00183	0.00996	CcSEcCtD
Droxidopa—Urinary tract infection—Clobazam—epilepsy syndrome	0.00179	0.00977	CcSEcCtD
Droxidopa—Cardiac failure congestive—Phenytoin—epilepsy syndrome	0.00177	0.00967	CcSEcCtD
Droxidopa—Confusional state—Amobarbital—epilepsy syndrome	0.00177	0.00963	CcSEcCtD
Droxidopa—ADRA1A—hindbrain—epilepsy syndrome	0.00174	0.019	CbGeAlD
Droxidopa—Shock—Amobarbital—epilepsy syndrome	0.00172	0.0094	CcSEcCtD
Droxidopa—Cardiac failure congestive—Carbamazepine—epilepsy syndrome	0.00169	0.00923	CcSEcCtD
Droxidopa—ADRA1D—forebrain—epilepsy syndrome	0.00168	0.0183	CbGeAlD
Droxidopa—PAH—brain—epilepsy syndrome	0.00158	0.0173	CbGeAlD
Droxidopa—ADRA1D—telencephalon—epilepsy syndrome	0.00154	0.0169	CbGeAlD
Droxidopa—Syncope—Phenobarbital—epilepsy syndrome	0.00145	0.00788	CcSEcCtD
Droxidopa—Feeling abnormal—Amobarbital—epilepsy syndrome	0.00144	0.00787	CcSEcCtD
Droxidopa—DDC—midbrain—epilepsy syndrome	0.00144	0.0157	CbGeAlD
Droxidopa—Urinary tract infection—Levetiracetam—epilepsy syndrome	0.00143	0.00782	CcSEcCtD
Droxidopa—Loss of consciousness—Phenobarbital—epilepsy syndrome	0.00142	0.00772	CcSEcCtD
Droxidopa—Urinary tract infection—Vigabatrin—epilepsy syndrome	0.00135	0.00735	CcSEcCtD
Droxidopa—Blood pressure increased—Gabapentin—epilepsy syndrome	0.00135	0.00734	CcSEcCtD
Droxidopa—Syncope—Lacosamide—epilepsy syndrome	0.00133	0.00726	CcSEcCtD
Droxidopa—Urinary tract infection—Diazepam—epilepsy syndrome	0.00133	0.00724	CcSEcCtD
Droxidopa—Confusional state—Phenobarbital—epilepsy syndrome	0.00133	0.00723	CcSEcCtD
Droxidopa—Loss of consciousness—Lacosamide—epilepsy syndrome	0.00131	0.00712	CcSEcCtD
Droxidopa—Shock—Phenobarbital—epilepsy syndrome	0.00129	0.00705	CcSEcCtD
Droxidopa—Urinary tract infection—Felbamate—epilepsy syndrome	0.00129	0.00701	CcSEcCtD
Droxidopa—Urinary tract infection—Zonisamide—epilepsy syndrome	0.00126	0.00686	CcSEcCtD
Droxidopa—DDC—head—epilepsy syndrome	0.00125	0.0136	CbGeAlD
Droxidopa—Arrhythmia—Propofol—epilepsy syndrome	0.00122	0.00668	CcSEcCtD
Droxidopa—Feeling abnormal—Trimethadione—epilepsy syndrome	0.00122	0.00667	CcSEcCtD
Droxidopa—Confusional state—Lacosamide—epilepsy syndrome	0.00122	0.00666	CcSEcCtD
Droxidopa—ADRB1—forebrain—epilepsy syndrome	0.00122	0.0133	CbGeAlD
Droxidopa—Urinary tract infection—Clonazepam—epilepsy syndrome	0.00121	0.00661	CcSEcCtD
Droxidopa—Urinary tract infection—Oxcarbazepine—epilepsy syndrome	0.0012	0.00653	CcSEcCtD
Droxidopa—Shock—Lacosamide—epilepsy syndrome	0.00119	0.0065	CcSEcCtD
Droxidopa—Confusional state—Clobazam—epilepsy syndrome	0.00119	0.00647	CcSEcCtD
Droxidopa—DDC—nervous system—epilepsy syndrome	0.00118	0.0129	CbGeAlD
Droxidopa—Cardiac failure congestive—Pregabalin—epilepsy syndrome	0.00118	0.00641	CcSEcCtD
Droxidopa—Dizziness—Amobarbital—epilepsy syndrome	0.00116	0.00632	CcSEcCtD
Droxidopa—Urinary tract infection—Carbamazepine—epilepsy syndrome	0.00115	0.00627	CcSEcCtD
Droxidopa—DDC—central nervous system—epilepsy syndrome	0.00114	0.0124	CbGeAlD
Droxidopa—ADRB1—telencephalon—epilepsy syndrome	0.00112	0.0122	CbGeAlD
Droxidopa—Dizziness—Primidone—epilepsy syndrome	0.00112	0.00609	CcSEcCtD
Droxidopa—Urinary tract infection—Lamotrigine—epilepsy syndrome	0.00111	0.00606	CcSEcCtD
Droxidopa—Headache—Amobarbital—epilepsy syndrome	0.0011	0.00598	CcSEcCtD
Droxidopa—Arrhythmia—Diazepam—epilepsy syndrome	0.0011	0.00597	CcSEcCtD
Droxidopa—Feeling abnormal—Phenobarbital—epilepsy syndrome	0.00108	0.00591	CcSEcCtD
Droxidopa—Cardiac failure congestive—Gabapentin—epilepsy syndrome	0.00108	0.00587	CcSEcCtD
Droxidopa—SLC6A2—brainstem—epilepsy syndrome	0.00107	0.0117	CbGeAlD
Droxidopa—Syncope—Propofol—epilepsy syndrome	0.00107	0.00583	CcSEcCtD
Droxidopa—Headache—Primidone—epilepsy syndrome	0.00106	0.00576	CcSEcCtD
Droxidopa—Confusional state—Acetazolamide—epilepsy syndrome	0.00106	0.00576	CcSEcCtD
Droxidopa—Loss of consciousness—Propofol—epilepsy syndrome	0.00105	0.00572	CcSEcCtD
Droxidopa—Syncope—Midazolam—epilepsy syndrome	0.00105	0.00571	CcSEcCtD
Droxidopa—Nausea—Amobarbital—epilepsy syndrome	0.00104	0.00567	CcSEcCtD
Droxidopa—SLC6A2—forebrain—epilepsy syndrome	0.00104	0.0113	CbGeAlD
Droxidopa—Shock—Acetazolamide—epilepsy syndrome	0.00103	0.00562	CcSEcCtD
Droxidopa—Hypertension—Propofol—epilepsy syndrome	0.00103	0.00562	CcSEcCtD
Droxidopa—Nausea—Primidone—epilepsy syndrome	0.001	0.00547	CcSEcCtD
Droxidopa—Feeling abnormal—Lacosamide—epilepsy syndrome	0.000999	0.00545	CcSEcCtD
Droxidopa—Syncope—Fosphenytoin—epilepsy syndrome	0.000998	0.00544	CcSEcCtD
Droxidopa—ADRA1A—brainstem—epilepsy syndrome	0.000998	0.0109	CbGeAlD
Droxidopa—Arrhythmia—Oxcarbazepine—epilepsy syndrome	0.000989	0.00539	CcSEcCtD
Droxidopa—Confusional state—Propofol—epilepsy syndrome	0.000982	0.00535	CcSEcCtD
Droxidopa—ADRA1B—head—epilepsy syndrome	0.000982	0.0107	CbGeAlD
Droxidopa—Loss of consciousness—Fosphenytoin—epilepsy syndrome	0.000978	0.00533	CcSEcCtD
Droxidopa—Feeling abnormal—Clobazam—epilepsy syndrome	0.00097	0.00528	CcSEcCtD
Droxidopa—ADRA1A—forebrain—epilepsy syndrome	0.000963	0.0105	CbGeAlD
Droxidopa—Confusional state—Midazolam—epilepsy syndrome	0.000961	0.00524	CcSEcCtD
Droxidopa—Hypertension—Fosphenytoin—epilepsy syndrome	0.000961	0.00524	CcSEcCtD
Droxidopa—ADRA1D—head—epilepsy syndrome	0.00096	0.0105	CbGeAlD
Droxidopa—Shock—Propofol—epilepsy syndrome	0.000958	0.00522	CcSEcCtD
Droxidopa—Syncope—Diazepam—epilepsy syndrome	0.000958	0.00522	CcSEcCtD
Droxidopa—SLC6A2—telencephalon—epilepsy syndrome	0.000953	0.0104	CbGeAlD
Droxidopa—Confusional state—Levetiracetam—epilepsy syndrome	0.000949	0.00517	CcSEcCtD
Droxidopa—Arrhythmia—Carbamazepine—epilepsy syndrome	0.000949	0.00517	CcSEcCtD
Droxidopa—Loss of consciousness—Diazepam—epilepsy syndrome	0.000939	0.00512	CcSEcCtD
Droxidopa—Shock—Midazolam—epilepsy syndrome	0.000938	0.00511	CcSEcCtD
Droxidopa—ADRA1B—nervous system—epilepsy syndrome	0.000931	0.0102	CbGeAlD
Droxidopa—Headache—Trimethadione—epilepsy syndrome	0.000931	0.00507	CcSEcCtD
Droxidopa—Confusional state—Fosphenytoin—epilepsy syndrome	0.000916	0.00499	CcSEcCtD
Droxidopa—ADRA1D—nervous system—epilepsy syndrome	0.00091	0.00995	CbGeAlD
Droxidopa—Syncope—Zonisamide—epilepsy syndrome	0.000907	0.00495	CcSEcCtD
Droxidopa—DDC—brain—epilepsy syndrome	0.000902	0.00986	CbGeAlD
Droxidopa—ADRA1B—central nervous system—epilepsy syndrome	0.000896	0.00979	CbGeAlD
Droxidopa—Shock—Fosphenytoin—epilepsy syndrome	0.000894	0.00487	CcSEcCtD
Droxidopa—Confusional state—Vigabatrin—epilepsy syndrome	0.000893	0.00487	CcSEcCtD
Droxidopa—Hypertension—Felbamate—epilepsy syndrome	0.000893	0.00486	CcSEcCtD
Droxidopa—Loss of consciousness—Zonisamide—epilepsy syndrome	0.000889	0.00485	CcSEcCtD
Droxidopa—ADRA1A—telencephalon—epilepsy syndrome	0.000886	0.00968	CbGeAlD
Droxidopa—Urinary tract infection—Valproic Acid—epilepsy syndrome	0.000883	0.00481	CcSEcCtD
Droxidopa—Nausea—Trimethadione—epilepsy syndrome	0.000882	0.00481	CcSEcCtD
Droxidopa—Confusional state—Diazepam—epilepsy syndrome	0.000879	0.00479	CcSEcCtD
Droxidopa—ADRA1D—central nervous system—epilepsy syndrome	0.000877	0.00958	CbGeAlD
Droxidopa—Hypertension—Zonisamide—epilepsy syndrome	0.000874	0.00476	CcSEcCtD
Droxidopa—Dizziness—Phenobarbital—epilepsy syndrome	0.00087	0.00474	CcSEcCtD
Droxidopa—Syncope—Phenytoin—epilepsy syndrome	0.000869	0.00473	CcSEcCtD
Droxidopa—Feeling abnormal—Acetazolamide—epilepsy syndrome	0.000864	0.00471	CcSEcCtD
Droxidopa—Syncope—Oxcarbazepine—epilepsy syndrome	0.000864	0.00471	CcSEcCtD
Droxidopa—Shock—Diazepam—epilepsy syndrome	0.000858	0.00467	CcSEcCtD
Droxidopa—Dizziness—Rufinamide—epilepsy syndrome	0.000854	0.00465	CcSEcCtD
Droxidopa—Loss of consciousness—Phenytoin—epilepsy syndrome	0.000851	0.00464	CcSEcCtD
Droxidopa—Confusional state—Felbamate—epilepsy syndrome	0.000851	0.00464	CcSEcCtD
Droxidopa—Loss of consciousness—Oxcarbazepine—epilepsy syndrome	0.000847	0.00462	CcSEcCtD
Droxidopa—ADRA2C—telencephalon—epilepsy syndrome	0.000844	0.00922	CbGeAlD
Droxidopa—Hypertension—Phenytoin—epilepsy syndrome	0.000836	0.00456	CcSEcCtD
Droxidopa—Confusional state—Zonisamide—epilepsy syndrome	0.000833	0.00454	CcSEcCtD
Droxidopa—Hypertension—Oxcarbazepine—epilepsy syndrome	0.000832	0.00453	CcSEcCtD
Droxidopa—Syncope—Carbamazepine—epilepsy syndrome	0.000829	0.00452	CcSEcCtD
Droxidopa—Headache—Phenobarbital—epilepsy syndrome	0.000824	0.00449	CcSEcCtD
Droxidopa—Loss of consciousness—Carbamazepine—epilepsy syndrome	0.000813	0.00443	CcSEcCtD
Droxidopa—Shock—Zonisamide—epilepsy syndrome	0.000813	0.00443	CcSEcCtD
Droxidopa—Headache—Rufinamide—epilepsy syndrome	0.000809	0.00441	CcSEcCtD
Droxidopa—Feeling abnormal—Propofol—epilepsy syndrome	0.000803	0.00437	CcSEcCtD
Droxidopa—Confusional state—Clonazepam—epilepsy syndrome	0.000803	0.00437	CcSEcCtD
Droxidopa—Dizziness—Lacosamide—epilepsy syndrome	0.000802	0.00437	CcSEcCtD
Droxidopa—Syncope—Lamotrigine—epilepsy syndrome	0.000801	0.00437	CcSEcCtD
Droxidopa—Urinary tract infection—Pregabalin—epilepsy syndrome	0.000799	0.00435	CcSEcCtD
Droxidopa—Hypertension—Carbamazepine—epilepsy syndrome	0.000798	0.00435	CcSEcCtD
Droxidopa—Confusional state—Phenytoin—epilepsy syndrome	0.000797	0.00434	CcSEcCtD
Droxidopa—Confusional state—Oxcarbazepine—epilepsy syndrome	0.000793	0.00432	CcSEcCtD
Droxidopa—Loss of consciousness—Lamotrigine—epilepsy syndrome	0.000785	0.00428	CcSEcCtD
Droxidopa—Feeling abnormal—Midazolam—epilepsy syndrome	0.000785	0.00428	CcSEcCtD
Droxidopa—Nausea—Phenobarbital—epilepsy syndrome	0.000781	0.00426	CcSEcCtD
Droxidopa—Dizziness—Clobazam—epilepsy syndrome	0.000778	0.00424	CcSEcCtD
Droxidopa—Shock—Phenytoin—epilepsy syndrome	0.000778	0.00424	CcSEcCtD
Droxidopa—Feeling abnormal—Levetiracetam—epilepsy syndrome	0.000776	0.00423	CcSEcCtD
Droxidopa—Shock—Oxcarbazepine—epilepsy syndrome	0.000774	0.00422	CcSEcCtD
Droxidopa—Hypertension—Lamotrigine—epilepsy syndrome	0.000772	0.0042	CcSEcCtD
Droxidopa—Nausea—Rufinamide—epilepsy syndrome	0.000767	0.00418	CcSEcCtD
Droxidopa—SLC16A10—cerebellum—epilepsy syndrome	0.000762	0.00833	CbGeAlD
Droxidopa—Confusional state—Carbamazepine—epilepsy syndrome	0.000761	0.00415	CcSEcCtD
Droxidopa—Headache—Lacosamide—epilepsy syndrome	0.00076	0.00414	CcSEcCtD
Droxidopa—Methyldopa—ADRA2A—epilepsy syndrome	0.000757	0.166	CrCbGaD
Droxidopa—Feeling abnormal—Fosphenytoin—epilepsy syndrome	0.000749	0.00408	CcSEcCtD
Droxidopa—SLC6A2—medulla oblongata—epilepsy syndrome	0.000749	0.00818	CbGeAlD
Droxidopa—Shock—Carbamazepine—epilepsy syndrome	0.000742	0.00405	CcSEcCtD
Droxidopa—Headache—Clobazam—epilepsy syndrome	0.000737	0.00402	CcSEcCtD
Droxidopa—Confusional state—Lamotrigine—epilepsy syndrome	0.000735	0.00401	CcSEcCtD
Droxidopa—ADRA2A—forebrain—epilepsy syndrome	0.000732	0.008	CbGeAlD
Droxidopa—Urinary tract infection—Gabapentin—epilepsy syndrome	0.000732	0.00399	CcSEcCtD
Droxidopa—Feeling abnormal—Vigabatrin—epilepsy syndrome	0.00073	0.00398	CcSEcCtD
Droxidopa—Arrhythmia—Valproic Acid—epilepsy syndrome	0.000729	0.00397	CcSEcCtD
Droxidopa—Nausea—Lacosamide—epilepsy syndrome	0.00072	0.00392	CcSEcCtD
Droxidopa—Feeling abnormal—Diazepam—epilepsy syndrome	0.000718	0.00391	CcSEcCtD
Droxidopa—Shock—Lamotrigine—epilepsy syndrome	0.000718	0.00391	CcSEcCtD
Droxidopa—ADRA1B—brain—epilepsy syndrome	0.000711	0.00778	CbGeAlD
Droxidopa—Nausea—Clobazam—epilepsy syndrome	0.000699	0.00381	CcSEcCtD
Droxidopa—ADRB1—head—epilepsy syndrome	0.000698	0.00762	CbGeAlD
Droxidopa—ADRA1D—brain—epilepsy syndrome	0.000696	0.00761	CbGeAlD
Droxidopa—Feeling abnormal—Felbamate—epilepsy syndrome	0.000695	0.00379	CcSEcCtD
Droxidopa—Dizziness—Acetazolamide—epilepsy syndrome	0.000694	0.00378	CcSEcCtD
Droxidopa—Feeling abnormal—Zonisamide—epilepsy syndrome	0.000681	0.00371	CcSEcCtD
Droxidopa—ADRA2A—telencephalon—epilepsy syndrome	0.000673	0.00736	CbGeAlD
Droxidopa—Levonordefrin—ADRA2A—epilepsy syndrome	0.000671	0.147	CrCbGaD
Droxidopa—ADRA2C—medulla oblongata—epilepsy syndrome	0.000663	0.00725	CbGeAlD
Droxidopa—ADRB1—nervous system—epilepsy syndrome	0.000661	0.00723	CbGeAlD
Droxidopa—Arrhythmia—Pregabalin—epilepsy syndrome	0.000659	0.00359	CcSEcCtD
Droxidopa—Headache—Acetazolamide—epilepsy syndrome	0.000657	0.00358	CcSEcCtD
Droxidopa—Feeling abnormal—Clonazepam—epilepsy syndrome	0.000656	0.00357	CcSEcCtD
Droxidopa—Feeling abnormal—Phenytoin—epilepsy syndrome	0.000652	0.00355	CcSEcCtD
Droxidopa—Feeling abnormal—Oxcarbazepine—epilepsy syndrome	0.000648	0.00353	CcSEcCtD
Droxidopa—Dizziness—Propofol—epilepsy syndrome	0.000644	0.00351	CcSEcCtD
Droxidopa—ADRB1—central nervous system—epilepsy syndrome	0.000637	0.00696	CbGeAlD
Droxidopa—Dizziness—Midazolam—epilepsy syndrome	0.00063	0.00343	CcSEcCtD
Droxidopa—Nausea—Acetazolamide—epilepsy syndrome	0.000623	0.0034	CcSEcCtD
Droxidopa—Dizziness—Levetiracetam—epilepsy syndrome	0.000622	0.00339	CcSEcCtD
Droxidopa—Feeling abnormal—Carbamazepine—epilepsy syndrome	0.000622	0.00339	CcSEcCtD
Droxidopa—Urinary tract infection—Topiramate—epilepsy syndrome	0.000616	0.00336	CcSEcCtD
Droxidopa—Hypertension—Valproic Acid—epilepsy syndrome	0.000613	0.00334	CcSEcCtD
Droxidopa—Headache—Propofol—epilepsy syndrome	0.00061	0.00333	CcSEcCtD
Droxidopa—ADRA2C—midbrain—epilepsy syndrome	0.000606	0.00662	CbGeAlD
Droxidopa—Feeling abnormal—Lamotrigine—epilepsy syndrome	0.000601	0.00328	CcSEcCtD
Droxidopa—Dizziness—Fosphenytoin—epilepsy syndrome	0.000601	0.00327	CcSEcCtD
Droxidopa—Headache—Midazolam—epilepsy syndrome	0.000597	0.00325	CcSEcCtD
Droxidopa—SLC6A2—head—epilepsy syndrome	0.000593	0.00648	CbGeAlD
Droxidopa—ADRA2C—spinal cord—epilepsy syndrome	0.000591	0.00646	CbGeAlD
Droxidopa—Headache—Levetiracetam—epilepsy syndrome	0.00059	0.00321	CcSEcCtD
Droxidopa—Dizziness—Vigabatrin—epilepsy syndrome	0.000586	0.00319	CcSEcCtD
Droxidopa—Confusional state—Valproic Acid—epilepsy syndrome	0.000584	0.00318	CcSEcCtD
Droxidopa—Nausea—Propofol—epilepsy syndrome	0.000579	0.00315	CcSEcCtD
Droxidopa—Dizziness—Diazepam—epilepsy syndrome	0.000576	0.00314	CcSEcCtD
Droxidopa—Syncope—Pregabalin—epilepsy syndrome	0.000576	0.00314	CcSEcCtD
Droxidopa—Headache—Fosphenytoin—epilepsy syndrome	0.000569	0.0031	CcSEcCtD
Droxidopa—Nausea—Midazolam—epilepsy syndrome	0.000566	0.00309	CcSEcCtD
Droxidopa—Loss of consciousness—Pregabalin—epilepsy syndrome	0.000564	0.00308	CcSEcCtD
Droxidopa—SLC6A2—nervous system—epilepsy syndrome	0.000562	0.00615	CbGeAlD
Droxidopa—Nausea—Levetiracetam—epilepsy syndrome	0.000559	0.00305	CcSEcCtD
Droxidopa—Dizziness—Felbamate—epilepsy syndrome	0.000558	0.00304	CcSEcCtD
Droxidopa—Headache—Vigabatrin—epilepsy syndrome	0.000555	0.00302	CcSEcCtD
Droxidopa—Hypertension—Pregabalin—epilepsy syndrome	0.000554	0.00302	CcSEcCtD
Droxidopa—ADRA1A—head—epilepsy syndrome	0.000552	0.00603	CbGeAlD
Droxidopa—Dizziness—Zonisamide—epilepsy syndrome	0.000546	0.00298	CcSEcCtD
Droxidopa—Headache—Diazepam—epilepsy syndrome	0.000546	0.00298	CcSEcCtD
Droxidopa—SLC6A2—central nervous system—epilepsy syndrome	0.000542	0.00592	CbGeAlD
Droxidopa—Nausea—Fosphenytoin—epilepsy syndrome	0.00054	0.00294	CcSEcCtD
Droxidopa—ADRA2A—medulla oblongata—epilepsy syndrome	0.000529	0.00578	CbGeAlD
Droxidopa—Headache—Felbamate—epilepsy syndrome	0.000529	0.00288	CcSEcCtD
Droxidopa—Confusional state—Pregabalin—epilepsy syndrome	0.000528	0.00288	CcSEcCtD
Droxidopa—Syncope—Gabapentin—epilepsy syndrome	0.000528	0.00288	CcSEcCtD
Droxidopa—Dizziness—Clonazepam—epilepsy syndrome	0.000526	0.00287	CcSEcCtD
Droxidopa—Nausea—Vigabatrin—epilepsy syndrome	0.000526	0.00287	CcSEcCtD
Droxidopa—ADRA2C—head—epilepsy syndrome	0.000526	0.00574	CbGeAlD
Droxidopa—ADRA1A—nervous system—epilepsy syndrome	0.000523	0.00572	CbGeAlD
Droxidopa—Dizziness—Phenytoin—epilepsy syndrome	0.000523	0.00285	CcSEcCtD
Droxidopa—Dizziness—Oxcarbazepine—epilepsy syndrome	0.00052	0.00283	CcSEcCtD
Droxidopa—Nausea—Diazepam—epilepsy syndrome	0.000518	0.00282	CcSEcCtD
Droxidopa—Loss of consciousness—Gabapentin—epilepsy syndrome	0.000517	0.00282	CcSEcCtD
Droxidopa—Headache—Zonisamide—epilepsy syndrome	0.000517	0.00282	CcSEcCtD
Droxidopa—Shock—Pregabalin—epilepsy syndrome	0.000516	0.00281	CcSEcCtD
Droxidopa—Hypertension—Gabapentin—epilepsy syndrome	0.000508	0.00277	CcSEcCtD
Droxidopa—ADRB1—brain—epilepsy syndrome	0.000505	0.00552	CbGeAlD
Droxidopa—ADRA1A—central nervous system—epilepsy syndrome	0.000503	0.0055	CbGeAlD
Droxidopa—Nausea—Felbamate—epilepsy syndrome	0.000501	0.00273	CcSEcCtD
Droxidopa—Dizziness—Carbamazepine—epilepsy syndrome	0.000499	0.00272	CcSEcCtD
Droxidopa—Headache—Clonazepam—epilepsy syndrome	0.000499	0.00272	CcSEcCtD
Droxidopa—ADRA2C—nervous system—epilepsy syndrome	0.000498	0.00545	CbGeAlD
Droxidopa—Headache—Phenytoin—epilepsy syndrome	0.000495	0.0027	CcSEcCtD
Droxidopa—Headache—Oxcarbazepine—epilepsy syndrome	0.000493	0.00268	CcSEcCtD
Droxidopa—ADRA1A—cerebellum—epilepsy syndrome	0.000492	0.00538	CbGeAlD
Droxidopa—Nausea—Zonisamide—epilepsy syndrome	0.000491	0.00267	CcSEcCtD
Droxidopa—Confusional state—Gabapentin—epilepsy syndrome	0.000484	0.00264	CcSEcCtD
Droxidopa—ADRA2A—midbrain—epilepsy syndrome	0.000484	0.00529	CbGeAlD
Droxidopa—Dizziness—Lamotrigine—epilepsy syndrome	0.000482	0.00263	CcSEcCtD
Droxidopa—ADRA2C—central nervous system—epilepsy syndrome	0.00048	0.00524	CbGeAlD
Droxidopa—Feeling abnormal—Valproic Acid—epilepsy syndrome	0.000478	0.0026	CcSEcCtD
Droxidopa—Nausea—Clonazepam—epilepsy syndrome	0.000473	0.00258	CcSEcCtD
Droxidopa—Headache—Carbamazepine—epilepsy syndrome	0.000473	0.00258	CcSEcCtD
Droxidopa—Shock—Gabapentin—epilepsy syndrome	0.000473	0.00258	CcSEcCtD
Droxidopa—ADRA2A—spinal cord—epilepsy syndrome	0.000472	0.00516	CbGeAlD
Droxidopa—Nausea—Phenytoin—epilepsy syndrome	0.00047	0.00256	CcSEcCtD
Droxidopa—ADRA2C—cerebellum—epilepsy syndrome	0.000469	0.00512	CbGeAlD
Droxidopa—Nausea—Oxcarbazepine—epilepsy syndrome	0.000467	0.00255	CcSEcCtD
Droxidopa—Headache—Lamotrigine—epilepsy syndrome	0.000457	0.00249	CcSEcCtD
Droxidopa—Nausea—Carbamazepine—epilepsy syndrome	0.000448	0.00244	CcSEcCtD
Droxidopa—Syncope—Topiramate—epilepsy syndrome	0.000444	0.00242	CcSEcCtD
Droxidopa—Loss of consciousness—Topiramate—epilepsy syndrome	0.000435	0.00237	CcSEcCtD
Droxidopa—Nausea—Lamotrigine—epilepsy syndrome	0.000433	0.00236	CcSEcCtD
Droxidopa—Feeling abnormal—Pregabalin—epilepsy syndrome	0.000432	0.00235	CcSEcCtD
Droxidopa—Dopamine—HTR7—epilepsy syndrome	0.000431	0.0945	CrCbGaD
Droxidopa—SLC6A2—brain—epilepsy syndrome	0.00043	0.0047	CbGeAlD
Droxidopa—Hypertension—Topiramate—epilepsy syndrome	0.000428	0.00233	CcSEcCtD
Droxidopa—ADRA2A—head—epilepsy syndrome	0.000419	0.00458	CbGeAlD
Droxidopa—Confusional state—Topiramate—epilepsy syndrome	0.000408	0.00222	CcSEcCtD
Droxidopa—ADRA1A—brain—epilepsy syndrome	0.0004	0.00437	CbGeAlD
Droxidopa—Norepinephrine—ADRA2A—epilepsy syndrome	0.000398	0.0872	CrCbGaD
Droxidopa—Shock—Topiramate—epilepsy syndrome	0.000398	0.00217	CcSEcCtD
Droxidopa—ADRA2A—nervous system—epilepsy syndrome	0.000398	0.00435	CbGeAlD
Droxidopa—Feeling abnormal—Gabapentin—epilepsy syndrome	0.000396	0.00216	CcSEcCtD
Droxidopa—Dizziness—Valproic Acid—epilepsy syndrome	0.000383	0.00209	CcSEcCtD
Droxidopa—ADRA2A—central nervous system—epilepsy syndrome	0.000383	0.00418	CbGeAlD
Droxidopa—ADRA2C—brain—epilepsy syndrome	0.000381	0.00416	CbGeAlD
Droxidopa—ADRA2A—cerebellum—epilepsy syndrome	0.000374	0.00409	CbGeAlD
Droxidopa—Headache—Valproic Acid—epilepsy syndrome	0.000363	0.00198	CcSEcCtD
Droxidopa—Epinephrine—ADRA2A—epilepsy syndrome	0.000361	0.0791	CrCbGaD
Droxidopa—Aminosalicylic Acid—PTGS2—epilepsy syndrome	0.00036	0.0788	CrCbGaD
Droxidopa—Dizziness—Pregabalin—epilepsy syndrome	0.000346	0.00189	CcSEcCtD
Droxidopa—Nausea—Valproic Acid—epilepsy syndrome	0.000344	0.00188	CcSEcCtD
Droxidopa—Epinephrine—TNF—epilepsy syndrome	0.000342	0.075	CrCbGaD
Droxidopa—Feeling abnormal—Topiramate—epilepsy syndrome	0.000333	0.00182	CcSEcCtD
Droxidopa—Headache—Pregabalin—epilepsy syndrome	0.000328	0.00179	CcSEcCtD
Droxidopa—Dizziness—Gabapentin—epilepsy syndrome	0.000318	0.00173	CcSEcCtD
Droxidopa—Nausea—Pregabalin—epilepsy syndrome	0.000311	0.0017	CcSEcCtD
Droxidopa—ADRA2A—brain—epilepsy syndrome	0.000304	0.00332	CbGeAlD
Droxidopa—Headache—Gabapentin—epilepsy syndrome	0.000301	0.00164	CcSEcCtD
Droxidopa—Nausea—Gabapentin—epilepsy syndrome	0.000285	0.00156	CcSEcCtD
Droxidopa—Mesalazine—PTGS2—epilepsy syndrome	0.000282	0.0618	CrCbGaD
Droxidopa—Dopamine—SLC6A4—epilepsy syndrome	0.000282	0.0618	CrCbGaD
Droxidopa—Dopamine—CYP2C19—epilepsy syndrome	0.000268	0.0586	CrCbGaD
Droxidopa—Dizziness—Topiramate—epilepsy syndrome	0.000267	0.00146	CcSEcCtD
Droxidopa—Headache—Topiramate—epilepsy syndrome	0.000253	0.00138	CcSEcCtD
Droxidopa—Nausea—Topiramate—epilepsy syndrome	0.00024	0.00131	CcSEcCtD
Droxidopa—L-DOPA—CYP2D6—epilepsy syndrome	0.000213	0.0467	CrCbGaD
Droxidopa—Dopamine—CYP2D6—epilepsy syndrome	0.000198	0.0434	CrCbGaD
Droxidopa—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	6.4e-06	2.42e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—FYN—epilepsy syndrome	6.4e-06	2.42e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AVP—epilepsy syndrome	6.39e-06	2.42e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	6.39e-06	2.41e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—H2AFX—epilepsy syndrome	6.37e-06	2.41e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	6.37e-06	2.41e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MEF2C—epilepsy syndrome	6.36e-06	2.4e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MTOR—epilepsy syndrome	6.33e-06	2.39e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—FYN—epilepsy syndrome	6.31e-06	2.39e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—H2AFX—epilepsy syndrome	6.29e-06	2.38e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CAT—epilepsy syndrome	6.28e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MEF2C—epilepsy syndrome	6.28e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	6.28e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	6.27e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	6.25e-06	2.36e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—YWHAZ—epilepsy syndrome	6.2e-06	2.34e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—YWHAZ—epilepsy syndrome	6.15e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HES1—epilepsy syndrome	6.14e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NGF—epilepsy syndrome	6.14e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AGT—epilepsy syndrome	6.13e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	6.11e-06	2.31e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TSC2—epilepsy syndrome	6.09e-06	2.3e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	6.09e-06	2.3e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AGT—epilepsy syndrome	6.08e-06	2.3e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NGF—epilepsy syndrome	6.08e-06	2.3e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—YWHAZ—epilepsy syndrome	6.07e-06	2.29e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HES1—epilepsy syndrome	6.05e-06	2.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—APOE—epilepsy syndrome	6.01e-06	2.27e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NGF—epilepsy syndrome	6e-06	2.27e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	5.97e-06	2.26e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—FYN—epilepsy syndrome	5.97e-06	2.26e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCR5—epilepsy syndrome	5.97e-06	2.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—APOE—epilepsy syndrome	5.96e-06	2.25e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—H2AFX—epilepsy syndrome	5.95e-06	2.25e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MEF2C—epilepsy syndrome	5.94e-06	2.25e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	5.94e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	5.94e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCR5—epilepsy syndrome	5.91e-06	2.23e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	5.88e-06	2.22e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—FYN—epilepsy syndrome	5.88e-06	2.22e-05	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—AKT1—epilepsy syndrome	5.87e-06	2.22e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	5.87e-06	2.22e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—H2AFX—epilepsy syndrome	5.86e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MEF2C—epilepsy syndrome	5.85e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—epilepsy syndrome	5.84e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCR5—epilepsy syndrome	5.84e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KDR—epilepsy syndrome	5.84e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	5.83e-06	2.2e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CASP3—epilepsy syndrome	5.82e-06	2.2e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	5.81e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—epilepsy syndrome	5.79e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—YWHAZ—epilepsy syndrome	5.74e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—epilepsy syndrome	5.71e-06	2.16e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—GPX1—epilepsy syndrome	5.68e-06	2.15e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	5.68e-06	2.15e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NGF—epilepsy syndrome	5.68e-06	2.15e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—YWHAZ—epilepsy syndrome	5.65e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—JUN—epilepsy syndrome	5.65e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PRKCB—epilepsy syndrome	5.62e-06	2.12e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6ST—epilepsy syndrome	5.6e-06	2.11e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NGF—epilepsy syndrome	5.59e-06	2.11e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TSC2—epilepsy syndrome	5.55e-06	2.1e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AGT—epilepsy syndrome	5.54e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCR5—epilepsy syndrome	5.52e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	5.52e-06	2.08e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MMP9—epilepsy syndrome	5.5e-06	2.08e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TSC2—epilepsy syndrome	5.5e-06	2.08e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AGT—epilepsy syndrome	5.49e-06	2.07e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—AKT1—epilepsy syndrome	5.47e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	5.46e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	5.45e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCR5—epilepsy syndrome	5.44e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—APOE—epilepsy syndrome	5.43e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TSC2—epilepsy syndrome	5.43e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AGT—epilepsy syndrome	5.42e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—epilepsy syndrome	5.41e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—APOE—epilepsy syndrome	5.38e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	5.37e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—AKT1—epilepsy syndrome	5.33e-06	2.02e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—epilepsy syndrome	5.32e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KDR—epilepsy syndrome	5.32e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—APOE—epilepsy syndrome	5.31e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	5.28e-06	1.99e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KDR—epilepsy syndrome	5.27e-06	1.99e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	5.22e-06	1.97e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KDR—epilepsy syndrome	5.2e-06	1.97e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	5.2e-06	1.97e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	5.19e-06	1.96e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—POMC—epilepsy syndrome	5.16e-06	1.95e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TSC2—epilepsy syndrome	5.14e-06	1.94e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AGT—epilepsy syndrome	5.13e-06	1.94e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PRKCB—epilepsy syndrome	5.12e-06	1.93e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—POMC—epilepsy syndrome	5.12e-06	1.93e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—AKT1—epilepsy syndrome	5.1e-06	1.93e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6ST—epilepsy syndrome	5.1e-06	1.93e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PRKCB—epilepsy syndrome	5.07e-06	1.92e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—SRC—epilepsy syndrome	5.07e-06	1.92e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TSC2—epilepsy syndrome	5.05e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6ST—epilepsy syndrome	5.05e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AGT—epilepsy syndrome	5.05e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—APOE—epilepsy syndrome	5.03e-06	1.9e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	5.02e-06	1.9e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PRKCB—epilepsy syndrome	5.01e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL2—epilepsy syndrome	5.01e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	4.99e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6ST—epilepsy syndrome	4.99e-06	1.88e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AGT—epilepsy syndrome	4.98e-06	1.88e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	4.96e-06	1.88e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—APOE—epilepsy syndrome	4.95e-06	1.87e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—VEGFA—epilepsy syndrome	4.94e-06	1.87e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KDR—epilepsy syndrome	4.92e-06	1.86e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—APOE—epilepsy syndrome	4.88e-06	1.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	4.85e-06	1.83e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KDR—epilepsy syndrome	4.85e-06	1.83e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	4.83e-06	1.83e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	4.83e-06	1.82e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	4.83e-06	1.82e-05	CbGpPWpGaD
Droxidopa—DDC—Metabolism—AKT1—epilepsy syndrome	4.76e-06	1.8e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PRKCB—epilepsy syndrome	4.74e-06	1.79e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	4.73e-06	1.79e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6ST—epilepsy syndrome	4.72e-06	1.78e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ALB—epilepsy syndrome	4.71e-06	1.78e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	4.66e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—POMC—epilepsy syndrome	4.66e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PRKCB—epilepsy syndrome	4.66e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6ST—epilepsy syndrome	4.65e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—POMC—epilepsy syndrome	4.62e-06	1.75e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	4.61e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL2—epilepsy syndrome	4.56e-06	1.72e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—POMC—epilepsy syndrome	4.56e-06	1.72e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—FGF2—epilepsy syndrome	4.53e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL2—epilepsy syndrome	4.52e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	4.49e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	4.49e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	4.48e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL2—epilepsy syndrome	4.46e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	4.39e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	4.39e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—POMC—epilepsy syndrome	4.32e-06	1.63e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	4.3e-06	1.63e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—POMC—epilepsy syndrome	4.25e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL2—epilepsy syndrome	4.22e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RELA—epilepsy syndrome	4.2e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—POMC—epilepsy syndrome	4.19e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	4.17e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	4.17e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL2—epilepsy syndrome	4.16e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	4.15e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	4.14e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	4.13e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—FGF2—epilepsy syndrome	4.12e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MTOR—epilepsy syndrome	4.12e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTGS2—epilepsy syndrome	4.12e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—FGF2—epilepsy syndrome	4.09e-06	1.54e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	4.08e-06	1.54e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—FGF2—epilepsy syndrome	4.03e-06	1.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	4e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	3.85e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	3.83e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RELA—epilepsy syndrome	3.83e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—AKT1—epilepsy syndrome	3.83e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ALB—epilepsy syndrome	3.82e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—FGF2—epilepsy syndrome	3.82e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RELA—epilepsy syndrome	3.79e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CASP3—epilepsy syndrome	3.79e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	3.77e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—FGF2—epilepsy syndrome	3.76e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MTOR—epilepsy syndrome	3.75e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RELA—epilepsy syndrome	3.75e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MTOR—epilepsy syndrome	3.72e-06	1.41e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	3.69e-06	1.4e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—JUN—epilepsy syndrome	3.68e-06	1.39e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MTOR—epilepsy syndrome	3.67e-06	1.39e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MMP9—epilepsy syndrome	3.58e-06	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RELA—epilepsy syndrome	3.54e-06	1.34e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	3.51e-06	1.32e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RELA—epilepsy syndrome	3.49e-06	1.32e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—epilepsy syndrome	3.49e-06	1.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MTOR—epilepsy syndrome	3.48e-06	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—epilepsy syndrome	3.47e-06	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.45e-06	1.3e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CASP3—epilepsy syndrome	3.45e-06	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	3.43e-06	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CASP3—epilepsy syndrome	3.42e-06	1.29e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MTOR—epilepsy syndrome	3.42e-06	1.29e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—epilepsy syndrome	3.41e-06	1.29e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CASP3—epilepsy syndrome	3.38e-06	1.28e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—JUN—epilepsy syndrome	3.35e-06	1.27e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	3.34e-06	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	3.34e-06	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—JUN—epilepsy syndrome	3.32e-06	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SRC—epilepsy syndrome	3.3e-06	1.25e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—JUN—epilepsy syndrome	3.28e-06	1.24e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MMP9—epilepsy syndrome	3.26e-06	1.23e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MMP9—epilepsy syndrome	3.23e-06	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—epilepsy syndrome	3.23e-06	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—epilepsy syndrome	3.22e-06	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CASP3—epilepsy syndrome	3.2e-06	1.21e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MMP9—epilepsy syndrome	3.19e-06	1.21e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.18e-06	1.2e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—epilepsy syndrome	3.17e-06	1.2e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—epilepsy syndrome	3.15e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CASP3—epilepsy syndrome	3.15e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—epilepsy syndrome	3.14e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—JUN—epilepsy syndrome	3.1e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	3.1e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	3.1e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—epilepsy syndrome	3.1e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—JUN—epilepsy syndrome	3.06e-06	1.15e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	3.04e-06	1.15e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MMP9—epilepsy syndrome	3.02e-06	1.14e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SRC—epilepsy syndrome	3.01e-06	1.14e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SRC—epilepsy syndrome	2.98e-06	1.13e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MMP9—epilepsy syndrome	2.97e-06	1.12e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SRC—epilepsy syndrome	2.94e-06	1.11e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—epilepsy syndrome	2.93e-06	1.11e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—epilepsy syndrome	2.93e-06	1.11e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—epilepsy syndrome	2.9e-06	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—epilepsy syndrome	2.88e-06	1.09e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	2.88e-06	1.09e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—epilepsy syndrome	2.87e-06	1.08e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	2.82e-06	1.07e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.82e-06	1.07e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	2.79e-06	1.06e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SRC—epilepsy syndrome	2.78e-06	1.05e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SRC—epilepsy syndrome	2.74e-06	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	2.71e-06	1.03e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—epilepsy syndrome	2.71e-06	1.02e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—epilepsy syndrome	2.67e-06	1.01e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	2.64e-06	9.98e-06	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.62e-06	9.9e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	2.6e-06	9.81e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	2.56e-06	9.68e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	2.52e-06	9.53e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	2.45e-06	9.27e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	2.43e-06	9.2e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	2.38e-06	8.99e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	2.37e-06	8.96e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	2.26e-06	8.55e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	2.2e-06	8.32e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—epilepsy syndrome	2.07e-06	7.82e-06	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—epilepsy syndrome	2.05e-06	7.75e-06	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—epilepsy syndrome	1.87e-06	7.07e-06	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—epilepsy syndrome	1.85e-06	7e-06	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—epilepsy syndrome	1.83e-06	6.91e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—epilepsy syndrome	1.73e-06	6.54e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—epilepsy syndrome	1.7e-06	6.44e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—epilepsy syndrome	1.68e-06	6.35e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	1.51e-06	5.72e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	1.41e-06	5.31e-06	CbGpPWpGaD
